TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00389883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two anesthetics protocol
Description: Comparison of two anesthetics protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of two anesthetics protocol
Description: Comparison of two anesthetics protocol
Study: NCT03910413

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duel Energy CT
Description: Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
Study: NCT02792361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Suction Drain
Description: The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
Study: NCT02647606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MILS
Description: MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MILS
Description: MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MILS
Description: MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Description: McGrath videolaryngoscope will be used for intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax AWS videolaryngoscope
Description: Pentax AWS videolaryngoscope will be used for intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Macintosh laryngoscope will be used for intubation
Study: NCT04382105

Intervention type: OTHER
Intervention: Observation of salivary IL-6 levels
Description: Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease

Intervention type: OTHER
Intervention: Observation of salivary IL-6 levels
Description: Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
Study: NCT04573621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic drain
Description: A pelvic drain is placed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pelvic drain is placed
Description: A pelvic drain is not placed
Study: NCT04424862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, ciclosporin and mycophenolate mofetil
Description: Multitarget Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponticelli Regimen
Description: Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
Study: NCT00289887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan +/- HCTZ
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
Study: NCT00698594

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sublingual allergen extract
Description: Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sublingual allergen extract
Description: Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
Study: NCT03310073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: Batch Number: 2042015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentabio
Description: Batch number: 5050115 The vaccine shall be given intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: The vaccine shall be given intramuscularly.
Study: NCT04392466

Intervention type: OTHER
Intervention: walking on the treadmill
Description: Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.

Intervention type: OTHER
Intervention: walking on the treadmill
Description: Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.

Intervention type: OTHER
Intervention: walking on the treadmill
Description: Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
Study: NCT03362450

Intervention type: OTHER
Intervention: Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination
Description: Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
Study: NCT03428425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel apatinib S-1
Description: HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery
Study: NCT03178786

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PAT sessions
Description: PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT sessions
Description: PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
Study: NCT04793919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: See the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: See the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic Trioxide
Description: See the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: See the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All-trans retinoic acid
Description: See the protocol
Study: NCT01888445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral
Study: NCT03382964

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
Study: NCT04047043

Intervention type: DIAGNOSTIC_TEST
Intervention: serum taurine
Description: blood sample for serum taurine level

Intervention type: DIAGNOSTIC_TEST
Intervention: serum taurine
Description: blood sample for serum taurine level

Intervention type: DIAGNOSTIC_TEST
Intervention: serum taurine
Description: blood sample for serum taurine level
Study: NCT03004521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetipatine prescribed in addition to the patient's existing antidepressant treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium prescribed in addition to the patient's existing antidepressant treatment.
Study: NCT00720122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin like growth factor-1 (rhIGF-1)
Description: Twice daily
Study: NCT01727245

Intervention type: OTHER
Group type: OTHER
Intervention: Obese
Description: gastric bypass

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Cholecystectomy and anti-reflux surgery
Study: NCT00908167

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Please see detailed description.

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Please see Detailed Description.
Study: NCT01183663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
Study: NCT01888445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: iv
Study: NCT04644705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to the interventional drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to the interventional drug
Study: NCT03641326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3x-BT
Description: Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3x-BT
Description: Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wGT3x-BT
Description: Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
Study: NCT00163761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, vinorelbine, ifosfamide, filgastrim
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, vinorelbine, filgastrim
Description: Drug
Study: NCT00030394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04500990

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d0.

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d0.

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d8±1.
Study: NCT01183663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose: 200 mg by mouth daily for 28 a day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose: 15 mg by vein every week for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by vein on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
Study: NCT01393782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angiotensin II
Description: All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
Study: NCT04535674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion
Study: NCT04500990

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d8±1.

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d30±2.

Intervention type: RADIATION
Intervention: MRI test
Description: Patients will receive diagnostic MRI test on d30±2.
Study: NCT04448444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Program Activating Therapy
Description: Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta reflex locomotion
Description: Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
Study: NCT04535674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asunercept
Description: Asunercept (APG101) will be administered once per week as an i.v. infusion
Study: NCT02295839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and Relaxation Education
Description: Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
Study: NCT00953264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: lifestyle intervention, including diet, physical activity and behavioral changes
Study: NCT04000568

Intervention type: OTHER
Intervention: Respiratory support: NAVA -NIV and PC-NIV
Description: The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
Study: NCT01886911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Training Intervention Game

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prosocial Training Intervention Game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control for Attention Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control for Prosocial Intervention
Study: NCT00792896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family conference
Description: family conference
Study: NCT02785341

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires every 6 weeks (T0, T1, T2, T3 and T4)
Description: Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires every 6 weeks (T0, T1, T2, T3 and T4)
Description: Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals

Intervention type: OTHER
Group type: OTHER
Intervention: 6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)

Intervention type: OTHER
Group type: OTHER
Intervention: 6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)

Intervention type: OTHER
Group type: OTHER
Intervention: leptin level with a blood test every 12 weeks (T0, T2 and T4)
Description: blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: leptin level with a blood test every 12 weeks (T0, T2 and T4)
Description: blood sample
Study: NCT02579954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study: NCT00787657

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
Study: NCT01259050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and Copper
Description: Optizinc 90 mg/d Copper 1 mg
Study: NCT01143688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol